FDA approved expanded age indication for EVO/EVO+ Visian implantable lenses

The company states: “STAAR Surgical (STAA) Company announced that the U.S. Food and Drug Administration has approved an expanded age indication for EVO/EVO+ Visian(R) Implantable Collamer Lenses, extending use to patients 21 to 60 years old. The approval came shortly after publication of three-year FDA clinical trial safety data, reinforcing the long-term safety profile of the EVO ICL.1 The EVO ICL was previously approved for U.S. patients 21 to 45 years old. The age range indication expansion helps to further increase the addressable market for the EVO ICL in the U.S. and allow its benefits to be brought to more patients. The achievement of the age range expansion in the U.S. is part of a continuing STAAR effort to expand our EVO ICL offering to a broader patient population globally.”